Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials

DOI10.1016/J.CSDA.2018.06.015MaRDI QIDQ1727847zbMATH OpenOpenAlexWikidataFDO

Authors Valeria Sambucini

Publication date 21 February 2019

Published in Computational Statistics and Data Analysis (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1016/j.csda.2018.06.015

zbMATH Keywords

phase II clinical trialsDirichlet-multinomial modelBayesian monitoringefficacy and safety endpointsposterior predictive probabilities

Mathematics Subject Classification ID

Computational methods for problems pertaining to statistics (62-08) Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10)

Recommendations

• Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials
• Bayesian prediction for two-stage sequential analysis in clinical trials
• An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints
• Practical Bayesian Guidelines for Phase IIB Clinical Trials
• Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach

Cites work

• scientific article; zbMATH DE number 578421 (Why is no real title available?)
• Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials
• Bayesian two-stage design for phase II clinical trials with switching hypothesis tests
• Bivariate Sequential Designs for Phase II Trials
• Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
• Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
• Incorporating Bayesian ideas into health-care evaluation
• Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
• Practical Bayesian Guidelines for Phase IIB Clinical Trials

Cited in

(9)

• Special issue on biostatistics
• Stopping for efficacy in single-arm phase II clinical trials
• An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints
• A Bayesian hierarchical monitoring design for phase cancer clinical trials: incorporating information on response duration into monitoring rules
• Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials
• A hybrid Bayesian-frequentist predictive design for monitoring multi-stage clinical trials
• Bayesian prediction for two-stage sequential analysis in clinical trials
• Monitoring Clinical Trials Based on Predictive Probability of Significance
• Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach

Describes a project that uses

Uses Software

• BOP2
• R

This page was built for publication: Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q1727847)